(Q38236320)

31 August 2017

title

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer (English)

1 reference

31 August 2017

1 reference

HaiXia Li

1

1 reference

31 August 2017

JianFang Zeng

series ordinal

2

1 reference

31 August 2017

Keng Shen

series ordinal

3

1 reference

31 August 2017

publication date

3 August 2014

1 reference

Archives of Gynecology and Obstetrics

31 August 2017

published in

1 reference

31 August 2017

volume

290

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

1067-1078

1 reference

https://scigraph.springernature.com/pub.10.1007/s00404-014-3377-3

31 August 2017

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Systemic therapy for ovarian cancer: current status and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Targeting the PI3K signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Oncogenic PI3K and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Status of PI3K inhibition and biomarker development in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Regulation of autophagy by phosphatidylinositol 3-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The regulation and function of Class III PI3Ks: novel roles for Vps34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Signaling by distinct classes of phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The PI3K-PDK1 connection: more than just a road to PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A new mutational AKTivation in the PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

New insights into ovarian cancer pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Genomic complexity and AKT dependence in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Chemically targeting the PI3K family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Targeting phosphoinositide 3-kinase: moving towards therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

mTOR Mediated Anti-Cancer Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

mTOR is a key modulator of ageing and age-related disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Current and future directions in mammalian target of rapamycin inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Targeting EGFR and PI3K pathways in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3377-3

10.1007/S00404-014-3377-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1008221109

0 references

1 reference